文献速递神经免疫

伊布地司特对进展型多发性硬化MRI指标的影响:SPRINT-MS二期研究

Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.
PubMed 文献 · Neurology · 2020-12-02

SPRINT-MS是一项随机、安慰剂对照、盲法研究,评估伊布地司特(最大100 mg)治疗原发性和继发性进展型多发性硬化96周对脑容量和新病灶的影响。共129例接受伊布地司特、126例接受安慰剂。结果显示伊布地司特使灰质萎缩减少35%(p=0.038),但新发/扩大T2病灶和新发T1低信号病灶无显著减少。

要点

  • 伊布地司特使进展型MS患者灰质萎缩减少35%(p=0.038)。
  • 伊布地司特未显著减少新发/扩大T2病灶(37.2% vs 29.0%,p=0.82)。
  • 伊布地司特未显著减少新发T1低信号病灶(33.3% vs 23.5%,p=0.11)。

核心结论

  • 伊布地司特治疗与灰质萎缩减少相关,但未减少新发或扩大T2病灶及新发T1病灶。
  • 伊布地司特可能影响神经退行性过程相关标志物,而非炎症过程。

研究设计与样本

  • 随机、安慰剂对照、盲法研究,评估伊布地司特最大100 mg治疗96周。
  • 纳入原发性或继发性进展型MS患者,伊布地司特组129例,安慰剂组126例。
  • 本次分析为既往报告试验的二次分析,包括次要和三级终点。

主要发现

  • 新发或扩大T2病灶:伊布地司特组37.2%,安慰剂组29.0%(p=0.82)。
  • 96周新发T1低信号病灶:伊布地司特组33.3%,安慰剂组23.5%(p=0.11)。
  • 灰质萎缩减少35%(伊布地司特 vs 安慰剂,p=0.038)。
  • SIENA测量的全脑萎缩进展减缓20%(p=0.08)。

关键数值与推荐

  • 新发或扩大T2病灶每24周评估一次,新发T1低信号病灶在96周评估。
  • 全脑萎缩通过SIENA作为敏感性分析。

临床怎么用

  • 伊布地司特可能用于减缓进展型MS的灰质萎缩,但对炎症性病灶活动无显著影响。
  • 临床决策需结合神经退行性标志物和炎症控制需求综合考虑。

局限性

  • 本研究为二次分析,部分终点为探索性。
  • 全脑萎缩进展减缓20%未达统计学显著性(p=0.08)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether ibudilast has an effect on brain volume and new lesions in progressive forms of multiple sclerosis (MS). METHODS: A randomized, placebo-controlled, blinded study evaluated ibudilast at a dose of up to 100 mg over 96 weeks in primary and secondary progressive MS. In this secondary analysis of a previously reported trial, secondary and tertiary endpoints included gray matter atrophy, new or enlarging T2 lesions as measured every 24 weeks, and new T1 hypointensities at 96 weeks. Whole brain atrophy measured by structural image evaluation, using normalization, of atrophy (SIENA) was a sensitivity analysis. RESULTS: A total of 129 participants were assigned to ibudilast and 126 to placebo. New or enlarging T2 lesions were observed in 37.2% on ibudilast and 29.0% on placebo (p = 0.82). New T1 hypointense lesions at 96 weeks were observed in 33.3% on ibudilast and 23.5% on placebo (p = 0.11). Gray matter atrophy was reduced by 35% for those on ibudilast vs placebo (p = 0.038). Progression of whole brain atrophy by SIENA was slowed by 20% in the ibudilast group compared with placebo (p = 0.08). CONCLUSION: Ibudilast treatment was associated with a reduction in gray matter atrophy. Ibudilast treatment was not associated with a reduction in new or enlarging T2 lesions or new T1 lesions. An effect on brain volume contributes to prior data that ibudilast appears to affect markers associated with neurodegenerative processes, but not inflammatory processes. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for people with MS, ibudilast does not significantly reduce new or enlarging T2 lesions or new T1 lesions.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Naismith RT, Bermel RA, Coffey CS, et al. Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study. Neurology. 2020. PMID: 33268562. doi:10.1212/WNL.0000000000011314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。